Source: https://www.buckingham.ac.uk/bitm/publications
Timestamp: 2019-04-26 15:37:49+00:00

Document:
Arch JRS. Comment on: ‘Schmidt MI, Duncan BB, Vigo A et al. (2006) Leptin and incident type 2 diabetes: risk or protection? Diabetologia 49:2086-2096.’ Diabetologia 2007 Jan;50(1):239–240. doi:10.1007/s00125-006-0523-x.
Yang CL, Kurczab T, Down G, Kealey T, Langlands K (2005). Gene expression profiling of the ageing rat vibrissa follicle. Br J Dermatol 153(1), 22–28.
Liu Y-L, Sennitt MV, Hislop DC, Crombie DL, Heyman RA, Cawthorne MA (2000). Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obesity 24, 997-1004.
Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, Park J, Chambers J, Sennitt MV, Stock MJ, Cawthorne MA, Young PW, Murphy GJ (1999). The tissue distribution of the human β3-adrenoceptor studied using a monoclonal antibody: direct evidence of the b3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obesity 23, 1057-1065.
Emilsson V, Arch JRS, de Groot RP, Lister CA, Cawthorne MA (1999). Leptin treatment increases suppressors of cytokine signaling in central and peripheral tissues. FEBS Lett 455, 170-174.
Morton NM, Emilsson V, de Groot RP, Pallett AL, Cawthorne MA (1999). Leptin signalling in pancreatic islets and clonal insulin-secreting cells. J Mol Endocrinol 22, 173-184.
Morton NM, de Groot RP, Cawthorne MA, Emilsson V (1999). Interleukin-1b activates a short STAT-3 isoform in clonal insulin-secreting cells. FEBS Lett 442, 57-60.
Emilsson V, Summers RJ, Hamilton S, Liu Y-L, Cawthorne MA (1998). The effects of the b3-adrenoceptor agonist BRL 35135 on UCP isoform mRNA expression. Biochem Biophys Res Commun 252, 450-454.
Morton NM, Emilsson V, Liu Y-L, Cawthorne MA (1998). Leptin action in intestinal cells. J Biol Chem 273, 26194-26201.
Cawthorne MA, Morton NM, Pallett AL, Liu Y-L, Emilsson V (1998). Peripheral metabolic actions of leptin. Proc Nutr Soc 57, 449-453.
Sennitt MV, Kaumann AJ, Molenaar P, Beeley LJ, Young PW, Kelly J, Chapman H, Henson SM, Berge JM, Dean DK, Kotecha NR, Morgan HKA, Rami HK, Ward RW, Thompson M, Wilson S, Smith SA, Cawthorne MA, Stock MJ, Arch JRS (1998). The contribution of classical ( b1/2 ) and atypical b-adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel b3-adrenoceptor agonists of different selectivities. J Pharm Exp Therap 285, 1084-1095.
Md. S. Islam, N.M. Morton, A. Hansson and V. Emilsson (1997). Rat insulinoma-derived pancreatic b-cells express a functional leptin receptor that mediates a proliferative response. Biochem. Biophys. Res. Commun. 238, 851-855.
A.L. Pallett, N.M. Morton, M.A. Cawthorne and V. Emilsson (1997). Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem. Biophys. Res. Commun. 238, 267-270.
Y.L. Liu, V. Emilsson and M.A. Cawthorne (1997). Leptin inhibits glycogen synthesis in the isolated soleus muscle of obese (ob/ob) mice. FEBS Lett. 411, 351-355.
V. Emilsson, Y.L. Liu, M.A. Cawthorne, N.M. Morton and M. Davenport (1997). Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 46, 313-316.
S.L. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and M. Tadayyon (1996). The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPARg and aP2 in adipose tissue of high fat fed rats. Biochem. Biophys. Res. Commun. 229, 752-757.
C. Deng, A. Paoloni-Giacobino, F. Kuehne, O. Boss, J-P. Revelli, M. Moinat, M.A. Cawthorne, P. Muzzin and J-P Giacobino (1996). Respective degree of expression of b1 , b2 and b3 -adrenoceptors in human brown and white adipose tissue. Br. J. Pharmacol. 118, 929-934. L.J. Beeley and M.A. Cawthorne (1996). Lean Prospects. Chem. Britain, May 31-34.
Y-L. Liu, M.A. Cawthorne and M.J. Stock (1996). Biphasic effects of the b-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle. Br. J. Pharmacol. 117, 1355-1361.
C. Stocker, E. Wargent, J. O’Dowd, R. Ngala, D. Carling, J. Arch and M. Cawthorne (2007). Patterns of postnatal growth impact on the early life programming of energy balance. Early Hum. Dev. 83, Suppl 1, S113, Abs P1-109.
M.A. Cawthorne, E. Wargent, M. Zaibi, C. Stott and S. Wright (2007). The CB-1 antagonist delta-9-tetrahydrocannabivarin (THCV) has anti-obesity activity in dietary-induced obese (DIO) mice. ‘17 Annual Symposium on the Cannabinoids’, Burlington, Vermont, International Cannabinoid Research Society, page 141.
C. Stocker, E. Wargent, K. Smith, J. O’Dowd, J. Arch and M. Cawthorne (2006). Early life programming of appetite by maternal leptin administration. Obes. Rev. 7, Suppl 2, 153, PO0132.
C. Stocker, E. Wargent, J. O’Dowd, D. Carling, J. Arch and M. Cawthorne (2006). Leptin supplementation in early life programmes muscle metabolism. Obes. Rev. 7, Suppl 2, 43, OP0015.
S. Wang, C. Cornick, J. O’Dowd and J. Arch (2005). Energy balance and glucose homeostasis in DGAT-1 homozygous and heterozygous knockout mice on chow and high fat diets. Obes. Res. 13, Suppl 1, A52, 202-P.
M. Cawthorne, E. Wargent, J. O’Dowd, D. Hislop, J. Arch and C. Stocker (2005). Pharmacologic treatment of dams programs offspring to resist diet-induced obesity. Obes. Res. 13, Suppl 1, A1, 2-OR.
J.R.S. Arch , S.J.Y. Wang, S. Birtles, D.M. Smith and A. Turnbull (2005). Effects of an inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 inhibitor on energy balance and glucose homeostasis in diet-induced obesity. Diabetologia 48, Suppl. 1, A238, Abs. 650.
J.F. O’Dowd, C. Cornick, C.J. Stocker, S.J.Y. Wang, M.A. Cawthorne and J.R S. Arch (2005). Identification of preprodynorphin as a pancreatic gene associated with increased susceptibility to diabetes. Diabetologia 48, Suppl. 1, A158, Abs. 425.
M.C.T. Fyfe, M.A. Cawthorne, M.V. Sennitt and R.L. Printz (2005). Antihyperglycemic effects of novel long- and short-acting glucokinase activators (PSN105 and PSN010) in diabetic animals. Diabetes 54, Suppl. 1, A129, Abs. 522-P.
P. Wong-Kai-In, M.A. Cawthorne, E. Wargent and G. Thomas (2005). PSN357, a novel glycogen phosphorylase inhibitor with anti-hyperglycemic efficacy in rodent models of diabetes. Diabetes 54, Suppl. 1, A140, Abs. 567-P.
J.R.S Arch, E. Wargent, M.V. Sennitt, C. Stocker, A.E.Mayes, L. Brown, J. O’Dowd, S. Wang, A.W.C. Einerhand, I. Mohede and M.A. Cawthorne (2005). Prolonged treatment of genetically obese mice with conjugated linoleic acid (CLA) improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Obes. Rev. 6, Suppl. 1, 43, Abs. T2: O103.
J.R. Arch, D. Hislop, S.J. Wang and J. Speakman (2005). Some mathematical and technical issues in open-circuit indirect calorimetry. Physiol. Res. 54(2), 9P.
S. Narayanan, A. Thomas, D. Shah, B. Gopalan, S. Vakkalanka and J. Arch (2004). A novel, orally active dipeptidyl peptidase IV inhibitor potently improves glucose tolerance in mice. Diabetologia 47, Suppl. 1, A285, Abs. 788.
R.A. Ngala, S. Wang, J. O’Dowd, M.A. Cawthorne and J.R.S. Arch (2004). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake in C2C12 cells: similarity with mouse soleus muscle pharmacology. Fundam. Clin. Pharmacol . 18, Suppl. 1, 36, Abs. P 04.22.
J.R.S. Arch (2004). β3-adrenoceptor agonists in obesity and type 2 diabetes: humans vs. rodents. Fundam. Clin. Pharmacol. 18, Suppl. 1, 11, Abs. S 09.2.
K. Smith, E. Wargent, A. Morrison, E. Grau, D. Smart, M. Cawthorne and J.Arch (2004). Normal suppression of feeding by leptin, but enhanced response to CB-1 receptor antagonists in BRS-3 knockout mice. Int. J. Obes. 28, Suppl. 1, S110, Abs. T3:P3-024.
S.J.Y. Wang and J. Arch, (2004). Reduced insulin sensitivity and glucose tolerance in DGAT-1 knockout mice. Int. J. Obes. 28, Suppl. 1, S90, Abs. T2:P2a-058.
N. Degabriele, S. Colombo, A. Medhurst, D. Sunter, J. Mercer and J. Arch, (2004). Insensitivity to tetrahydrocannabinol in rats sensitive to diet-induced obesity. Int. J. Obes. 28, Suppl. 1, S47, Abs. T7d:O1-006.
K. Smith; A. Haynes; H. Chapman, D. Smart and J.R.S. Arch (2004). Central administration of a bombesin receptor-2 agonist abolishes the anorexic effect of bombesin in refed rats Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 029P.
R. A. Ngala; S.J.Y. Wang, M. A. Cawthorne and J. R.S. Arch (2004). Biphasic and atypical pharmacology of glucose uptake in mouse isolated soleus muscle is dependent on the β2-adrenoceptor Br. Pharmacol. Soc. Pa2 online Vol 2(1), Abs. 008P.
S. Wang, M.A. Cawthorne, J.R.S. Arch and J.C. Clapham (2003). Increased adiposity and low leptin in transgenic mice overexpressing UCP-3 in skeletal muscle after long term high fat feeding. Obes. Res. 11(9), Suppl, A30, Abs. 122-OR.
R. Ngala, S. Wang, M.A. Cawthorne and J.R.S. Arch (2003). Atypical pharmacology and opposing effects of β-adrenoceptor agonists on glucose uptake and pyruvate oxidation in skeletal muscle. Diabetologia 46, Suppl. 2, A210, Abs. 606.
G. Schmid, V. Converset, N. Walter, M. Sennitt, M. Ward, M. Cawthorne and J.-C. Sanchez (2003). Effect of high fat diet on the expression of proteins in muscle, adipose tissues and liver of C57Bl/6 mice. Diabetologia 46, Suppl. 2, A207, Abs. 596.
E.T. Wargent, M.V. Sennitt, C.-W. Woon and M.A. Cawthorne (2003). The DPPIV resistant GLP-1 analogue, BIM 51077, improves diabetic control in ZDF rats. Diabetologia 46, Suppl. 2, A169, Abs. 482.
C. Stocker, N.M. Morton, E. Wargent, J. O’Dowd, M.V. Sennitt, D. Hislop, J. Seckl, J.R.S. Arch and M.A. Cawthorne (2003). Leptin administration prevents reduction of placental 11β-hydroxysteroid dehydrogenase-2 associated with maternal protein restriction and prevents obesity in male offspring in a rat model of in utero growth retardation. Pediatr. Res. 53 (6), Suppl., p. 41A, Abs. P.628.
C. Stocker, E. Wargent, J. O’Dowd, M.V. Sennitt, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2003). Maternal leptin administration attenuates high fat diet-induced insulin resistance in female offspring in a rodent model of in utero growth restriction without affecting adiponectin. Pediatr. Res. 53 (6), Suppl., p. 29A, Abs. P.337.
K. Smith, A. Medhurst, C. Stocker, D. Smart and J. Arch (2003). Expression of mRNA for bombesin receptors in hypothalami of fa/fa and fasted rats. Int. J. Obesity 27, Suppl. 1, S65, Abs. P1-091.
C. Stocker, E. Wargent, M.V. Sennitt, J. O’Dowd, D. Hislop, J.R.S. Arch and M.A. Cawthorne (2002). Administration of leptin to pregnant rats fed on a low protein diet prevents high fat diet induced insulin resistance in male offspring. Diabetes 51, Suppl 2, A144, Abs. 582-P.
S. Wang, A. Subramaniam, M.A. Cawthorne and J.C. Clapham (2001). Substrate oxidation in mice over-expressing human UCP-3 in skeletal muscle. Obesity Research 9, Suppl. 3, 113S, Abs. PB28.
C. Stocker, E. Wargent, M. Sennitt, A. Nolan, J. O’Dowd, K. Subramaniam, S. Wang and M. Cawthorne (2001). Maternal leptin administration induces resistance to diet-induced obesity of early growth restricted rats. Diabetologia 44, Suppl 1, A167, Abs 641.
A. Subramaniam, C. Stocker, M.V. Sennitt, S. Wang, A.L. Nolan, L. Brown, M. Bertrand, A. Peilow, A. Mayes and M.A. Cawthorne (2001). Guggul lipid reduces insulin resistance and body weight gain in C57Bl/6 lep/lep mice. Int. J. Obesity 25, Suppl. 2, S24, Abs. O66.
V. Emilsson, J. O’Dowd, A.L. Pallett and M.A. Cawthorne (2001). Hexosamine and nutrient excess induce leptin production and leptin receptor activation in islet b cells. Diabetes 50, Suppl. 2, A343, Abs. 1428.
C. Stocker, E. Wargent, A. Subramaniam, H-U. Demuth, M. Sennitt and M.A. Cawthorne (2001). The dipeptidyl peptidase inhibitor P32/98 improves glucose tolerance in diabetic ZDF rats. Diabetes 50, Suppl. 2, A522, Abs. 2200.
J.-C. Sanchez, D. Chiappe, M.V. Sennitt, V. Rouge, S. Wang, A.L. Pallett, D. Hochstrasser and M. Cawthorne (2000). Effects of the insulin sensitiser drug, rosiglitazone, on the differential expression of obesity-associated liver cytosolic and nuclear proteins of lep/lep mice. Obesity Research 8, Suppl. 1, 125S, Abs. PF38.
M.A. Cawthorne, K. Clavurier, C. Stocker, E. Whittle, A. Subramaniam, I. Rubin and M.V. Sennitt (2000). P57, a plant derived anorexic agent, reduces food intake and normalises blood glucose in ZDF rats. Obesity Research 8, Suppl. 1, 81S. Abs. PB55.
E. Wargent, A.L. Nolan, Y. Shen, J. Dong, J.E. Taylor, M. Culler, B. Morgan, C-W. Woon and M.A. Cawthorne (2000). Insulin secretagogue activity in vitro and in perfused pancreas of dipeptidase IV resistant GLP-1 analogues. Diabetologia 43, Suppl 1, A137, Abs 532.
A.L. Nolan, M.V. Sennitt, E.B. Whittle, C.J. Stocker and M.A. Cawthorne (2000). Acute and chronic effects of exendin-4 on glycaemic control and food intake in diabetic mice. Diabetologia 43, Suppl 1, A148, Abs 572.
M. Board, F. Preitner, J-P. Giacobino and M.A. Cawthorne (2000). The b3 -adrenoceptor agonist, BRL 37344, increases pyruvate and palmitate oxidation in soleus muscle of b3 -KO mice. Int. J. Obesity 24, Suppl 1, Abs 80, S30.
A.C. Haynes, B. Jackson, M.A. Cawthorne, S. Wilson, M. Tadayyon and J.R.S. Arch (2000). Interactions of the orexins and melanin concentrating hormone on feeding. Int. J. Obesity 24, Suppl 1, Abs 101, S37.
J-C. Sanchez, V. Rouge, D. Hochstrasser, M.V. Sennitt, S. Wang, A.L. Pallett and M.A. Cawthorne (2000). Effect of rosiglitazone on the differential expression of diabetes associated proteins in pancreatic islets of C57BI/6J lep/lep mice. Diabetes 49, Suppl 1, Abs 1041-P, A250.
M. Board, P. Doyle and M.A. Cawthorne (1999). Stimulation of oxidative metabolism of isolated skeletal muscle by b3-adrenoceptor (b3-AR) agonists: evidence for the existence of a novel b-AR in murine soleus muscle. Diabetes 48, Suppl 1, Abs 1991.
V. Emilsson, J. O’Dowd, S. Wang, R. Heyman and M. Cawthorne (1999). Effects of rexinoids and thiazolidinedione on levels of UCP isoforms and PGC-1 in the obese Zucker rat. Diabetologia 42, Suppl 1, A 206, Abs 774.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, C.A. Lister (1998). Rosiglitazone reduces overexpression of insulin and amylin mRNA in hypertrophied pancreatic islets. Diabetologia 41, Suppl 1, A169, abs 659.
C.A.Lister, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and S.A. Smith (1998). Rosiglitazone increases pancreatic islet cell area, number and insulin content, but not insulin gene expression. Diabetologia 41, Suppl 1, A169, abs 660.
A.L. Pallett, V. Emilsson, D. Coy, J. Taylor, C.-W. Woon and M.A. Cawthorne (1998). Reduced expression of somatostatin receptor sub-types in Zucker rat islets and functional typing of the somatostatin induced inhibition of insulin secretion. Diabetologia 41, Suppl 1, A152, abs 592.
V. Emilsson, J. Arch, R.P. De Groot, A.M. Kanu, Y-L. Liu, N.M. Morton, A.L. Pallett, C.A. Lister and M.A. Cawthorne (1998). A role for suppressors of leptin signalling in the states of leptin resistance. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.
V. Emilsson, R.J. Summers, Y-L. Liu, A.M. Kanu, M.A. Cawthorne (1998). The effect of the b3-adrenoceptor agonist BRL 35135 on UCP-2 and UCP-3 mRNA levels in vivo. Presented at Symposium on Genetic and Molecular Basis of Obesity, Paris, 26-28 August 1998.
M.A. Cawthorne (1998). Thiazolidinediones in the treatment of Insulin Resistance Syndrome. Int. J. Obesity 22, Suppl 3, S86, abs O314.
M.A. Cawthorne, P.D. Chamberlain, K.H. Jennings, F. Paul, J. Cordell, A. Berry, S.D. Holmes, J. Park, J. Chambers, M.V. Sennitt, M.J. Stock, P.W. Young and G.J. Murphy (1998). Direct evidence of a b3-adrenoceptor expression in human adipose tissue, atrium and skeletal muscle obtained using a novel monoclonal antibody. Int. J. Obesity 22, Suppl 3, S74, abs O267.
M. Board and M.A. Cawthorne (1998). Abnormal response of glucose uptake by soleus muscle from ob/ob mice to BRL 37344. Int. J. Obesity 22, Suppl 3, S189, abs P355.
Y.-L. Liu, M.V. Sennitt, D.C. Hislop, D.L. Crombie, R.A. Heyman and M.A. Cawthorne (1998). Rexinoid X receptor agonists improve insulin sensitivity and have anti-obesity effects in Zucker fa/fa rats. Diabetes 47, Suppl 1, A283, abs 1099.
S.A. Smith, D. Boam, M.A. Cawthorne, J. Sidaway, M. Newman, M. Wilkinson, S. Dunmore, and C.A. Lister (1998). Rosiglitazone improves insulin sensitivity and reduces hyper-expression of insulin and amylin mRNAs in pancreatic islets. Diabetes 47, Suppl 1, A94. abs 0365.
S.A. Smith, D. Boam, D. Bretherton-Watt, M.A. Cawthorne, G. Moore, S. Loughborough, J. Warrack, M. Wilkinson and C.A.Lister (1998). Rosiglitazone increases pancreatic islet cell area, density and insulin content, but not insulin gene expression. Diabetes 47, Suppl 1, A18, abs 0072.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1998). Leptin signalling in pancreatic beta cells. British Diabetic Association, Edinburgh.
N.M. Morton, V. Emilsson and M.A. Cawthorne (1998). Interleukin 1b induces a novel STAT-DNA binding activity in the insulin secreting cell line Rin m5F. Keystone symposium on JAK and STAT signalling.
N.M. Morton, V. Emilsson, A.L. Pallett and M.A. Cawthorne (1997). Leptin-induced tyrosine phosphorylation in islets from ob/ob mice. Exp. Clin. Endocrinol. Diabetes 105, 4, A35.
A.L. Pallett, N.M. Morton, V. Emilsson and M.A. Cawthorne (1997). Effect of leptin on glucose stimulated insulin secretion in isolated rat islets. Exp. Clin. Endocrinol. Diabetes 105, 4, A41.
S. Pearson, M.A. Cawthorne, J.C. Clapham, S.J. Dunmore, S.D. Holmes, G.B.T. Moore, S.A. Smith and Tadayyon, M. (1997). The insulin sensitiser, BRL 49653, increases expression of PPAR-g and aP2 mRNA but does not effect UCP or b3-AR mRNA. Int. J. Obesity 21, Suppl 2, 180, S61.
V. Emilsson, N. Cheung, M.V. Sennitt and M.A. Cawthorne (1997). Melanin concentrating hormone stimulates leptin secretion from adipocytes. Diabetologia 40, Suppl 1, 678, A173.
Y.L. Liu, V. Emilsson, and M.A. Cawthorne (1997). Inhibition of glycogen synthesis by leptin in isolated soleus muscle of obese (ob/ob) mice. Int. J. Obesity 21, Suppl 2, 23, S13.
M.A. Cawthorne, Y.L. Liu, Morton, N., Davenport, M. and Emilsson, V. (1997). Is there a role for leptin in the development of NIDDM? Diabetic Med.
Ibrahim M, Jassim S, Cawthorne MA, Langlands (2013). A Pathway Enrichment and Gene Network Analysis Method for Biomarker Identification, Biotrinity Meeting 2013, Newbury, Berkshire, UK, 14-16 May 2013.
Stocker CJ (ed.). Type 2 Diabetes: Methods and Protocols (London: Humana Press, 2009).
Arch JRS. How might regulators’ expectations of novel anti-obesity drugs be achieved? The Diabetes Report. 2008 Jan: pp1–4.
Arch JRS. Thermogenesis and related targets for anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp143–160.
Cawthorne MA. Promising new targets for the next generation of anti-obesity drugs. In: Obesity and Metabolic Disorders (Amsterdam: IOS Press, 2005), ed. Antel J., Finer N, Heal D and Krause G., pp201–214.
Cawthorne MA, Heald M. Leptin (Amgen). Curr. Opin. Oncol. Endocrine Metabol. Invest. Drugs 2000 2: pp217–226.

References: V. 
 V. 
 V. 

V. 
 V. 

V. 
 V. 
 V. 

V. 
 V. 

V. 

V. 
 V. 
 V. 
 V. 
 V. 

V. 
 V. 
 V.